VIA
JBIO

Virtus Investment Advisers’s Jade Biosciences JBIO Stock Holding History

Virtus Investment Advisers’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$256K Buy
18,203
+444
+3% +$6.43K 0.07% 312
2025
Q4 		$274K Buy
+17,759
New +$208K 0.07% 283

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Virtus Investment Advisers's JBIO Position: Q1 2026 in Review

Virtus Investment Advisers increased its Jade Biosciences (JBIO) stake by 2.5% in Q1 2026, buying an estimated $6.43K and bringing the position to 18,203 shares worth $256K. The position accounts for 0.07% of the portfolio, ranked #312.

Virtus Investment Advisers first reported a position in JBIO in Q4 2025 and has held it in 2 quarters since. The position peaked at $274K in Q4 2025. 120 funds tracked by Wall St. Rank hold JBIO as of Q1 2026.

  • Virtus Investment Advisers held 18,203 shares of Jade Biosciences worth $256K as of Q1 2026.
  • Virtus Investment Advisers bought 444 Jade Biosciences shares in Q1 2026, an estimated $6.43K.
  • Jade Biosciences made up 0.07% of Virtus Investment Advisers's portfolio in Q1 2026, its #312 holding.
  • Virtus Investment Advisers first reported a position in Jade Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Virtus Investment Advisers's Jade Biosciences position peaked at $274K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Jade Biosciences as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.